(Reuters) – Gilead Sciences (NASDAQ:GILD) said on Friday it was voluntarily withdrawing the U.S. approval for Trodelvy in previously treated patients with a type of urothelial cancer after consultation with the regulator.
You May Also Like
Latest News
Vice President Kamala Harris’s doctor said in a letter Saturday that she is in “excellent health” as she released her first medical report in...
Latest News
New majorities in Congress, particularly when the incoming party has a new leader, offer the rare chance for the institution to take a breath...
Latest News
Donald Trump is leaning into a nativist, anti-immigrant message in the final stage of his third presidential campaign, advancing a closing argument centered on...
Latest News
The Gateway Pundit, a far-right website, published a note from its editor on Saturday acknowledging that two election workers in Georgia did not engage...